Each of our programs is guided by compelling genetics and a clear understanding of target mechanisms and their impact on disease. With our breakthrough computational platform we engineer selective and potent therapeutics that solve long-standing challenges, resulting in medicines with unprecedented potency, selectivity and pharmacokinetics.
Discoveries from the ‘omics revolution have produced hundreds of biologically important targets, many of which have proven unreachable by traditional small molecule drug development. Our diverse pipeline of first-in-class medicines comprises highly desirable disease targets in metabolic disease, oncology and inflammation that have proven inaccessable to traditional chemistry approaches.
We obliterate the boundaries between discovery, chemistry and pharmacology – and between Nimbus and our network of collaborators. Applying our novel drug discovery paradigm and working seamlessly together as an integrated ecosystem, we accelerate the path from discovery to the clinic.
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.
September 9, 2015
Nimbus Therapeutics Appoints Annie C. Chen,, M.D., M.P.H., as Chief Medical Officer
July 7, 2015
Nimbus Therapeutics Appoints Mark Iwicki and George Vlasuk to its Board of Directors
© 2015 Nimbus Therapeutics